产品说明书

Pyridostigmine bromide

Print
Chemical Structure| 101-26-8 同义名 : 溴吡斯的明 ;Pyridostigmine (bromide);Ro 1-5130;Pyridostigmine Br, Pyridostigmine;Kalimin;Regonol;Mestinon;NSC 679759
CAS号 : 101-26-8
货号 : A725388
分子式 : C9H13BrN2O2
纯度 : 99+%
分子量 : 261.116
MDL号 : MFCD00079283
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(191.49 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 8.5 mg/mL(32.55 mM)
动物实验配方：
生物活性
靶点

  • AChR
描述 Pyridostigmine bromide, a reversible inhibitor of cholinesterase, has been used to treat myasthenia gravis, reverse neuromuscular blockade, and prevent nerve gas (ie, soman) poisoning[3]. Pyridostigmine bromide may act on the heart, at least partially increasing the vagal parasympathetic activity, via the accumulation of acetylcholine in the myocardium[4]. Pyridostigmine(Bromide) significantly attenuated cardiac hypertrophy based on reduction in left ventricular weight/body weight, suppression of the levels of atrial natriuretic peptide, brain natriuretic peptide and β‐myosin heavy chain, and a reduction in cardiac fibrosis. [5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03619759 - Recruiting August 31, 2019 Korea, Republic of ... 展开 >> Ajou university school of medicine Recruiting Suwon, Gyeonggi-do, Korea, Republic of, 16377 Contact: In Kyong Yi, MD 收起 <<
NCT00624663 Rivastigmine Toxicity Not Applicable Completed - Israel ... 展开 >> Tel Aviv Sourasky Medical Center Tel Aviv, Israel Tasmc Clinical Research Center Tel-Aviv, Israel, 64239 收起 <<
NCT03468452 - Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.83mL

0.77mL

0.38mL

19.15mL

3.83mL

1.91mL

38.30mL

7.66mL

3.83mL
参考文献

[1]Kanjwal K, Karabin B, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011 Jun;34(6):750-5.

[2]Gales BJ, Gales MA. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother. 2007 Feb;41(2):314-8.

[3]Tan Q, Jiang R, Xu M, Liu G, Li S, Zhang J. Nanosized sustained-release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics. Int J Nanomedicine. 2013;8:737-45. doi: 10.2147/IJN.S40860. Epub 2013 Feb 20. PMID: 23459707; PMCID: PMC3582480.

[4]de Cuba MB, Machado MP, Farnesi TS, Alves AC, Martins LA, de Oliveira LF, Capitelli CS, Leite CF, Silva MV, Machado JR, Kappel HB, de Campos HS, Paiva L, Gomes NL, Faleiros AC, Britto CF, Savino W, Moreira OC, Rodrigues V Jr, Montano N, Lages-Silva E, Ramirez LE, da Silva VJ. Effects of cholinergic stimulation with pyridostigmine bromide on chronic chagasic cardiomyopathic mice. Mediators Inflamm. 2014;2014:475946. doi: 10.1155/2014/475946. Epub 2014 Aug 24. PMID: 25221388; PMCID: PMC4158292.

[5]Lu Y, Zhao M, Liu JJ, He X, Yu XJ, Liu LZ, Sun L, Chen LN, Zang WJ. Long-term administration of pyridostigmine attenuates pressure overload-induced cardiac hypertrophy by inhibiting calcineurin signalling. J Cell Mol Med. 2017 Sep;21(9):2106-2116. doi: 10.1111/jcmm.13133. Epub 2017 Mar 10. PMID: 28296184; PMCID: PMC5571547.